Endothelial transcripts uncover a previously unknown phenotype: C4d-negative antibody-mediated rejection

Current Opinion in Organ Transplantation

Volumn 15, Issue 1, 2010, Pages 42-48

  Sis, Banu ^a,b   Halloran, Philip F ^a,b  

^a UNIVERSITY OF ALBERTA   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Antibody mediated rejection; C4d; Donor specific antibody; Endothelial gene expression; Microarrays

Indexed keywords

ALLOANTIBODY; ANTIBODY; COMPLEMENT COMPONENT C4D; COMPLEMENT COMPONENT C4D NEGATIVE; FC RECEPTOR; GAMMA INTERFERON; LEUKOCYTE ANTIGEN; LEUKOCYTE ANTIGEN ALLOANTIBODY; UNCLASSIFIED DRUG;

ANTIBODY MEDIATED REJECTION; ENDOTHELIUM CELL; GENE EXPRESSION; GRAFT REJECTION; GRAFT SURVIVAL; HISTOPATHOLOGY; HUMAN; INFLAMMATION; KIDNEY ALLOGRAFT; KIDNEY BIOPSY; KIDNEY GRAFT; LEUKOCYTE; MICROARRAY ANALYSIS; MICROCIRCULATION; MOLECULAR BIOLOGY; MOLECULAR MECHANICS; ORGAN TRANSPLANTATION; OUTCOME ASSESSMENT; PHENOTYPE; REVIEW; STAINING; THROMBOCYTE;

BIOLOGICAL MARKERS; BIOPSY; COMPLEMENT C4B; ENDOTHELIAL CELLS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GRAFT REJECTION; HLA ANTIGENS; HUMANS; IMMUNITY, HUMORAL; IMMUNOHISTOCHEMISTRY; ISOANTIBODIES; KIDNEY; KIDNEY TRANSPLANTATION; MICROVESSELS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PEPTIDE FRAGMENTS; PHENOTYPE; PREDICTIVE VALUE OF TESTS; RNA, MESSENGER; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 75749105115     PISSN: 10872418     EISSN: 15317013     Source Type: Journal    
DOI: 10.1097/MOT.0b013e3283352a50     Document Type: Review

References (68)

1. U. S. Renal Data System, USRDS 2008 Annual Data Report: atlas of chronic kidney disease and end-stage renal disease in the United States, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases. Bethesda, MD; 2008.
2. Einecke G, Melk A, Ramassar V, et al. Expression of CTL associated transcripts precedes the development of tubulitis in T-cell mediated kidney graft rejection. Am J Transplant 2005; 5:1827-1836.
3. Famulski KS, Einecke G, Reeve J, et al. Changes in the transcriptome in allograft rejection: IFN-g induced transcripts in mouse kidney allografts. Am J Transplant 2006; 6:1342-1354.
4. Mueller TF, Einecke G, Reeve J, et al. Microarray analysis of rejection in human kidney transplants using pathogenesis-based transcript sets. Am J Transplant 2007; 7:2712-2722.
5. Einecke G, Broderick G, Sis B, Halloran PF. Early loss of renal transcripts in kidney allografts: relationship to the development of histologic lesions and alloimmune effector mechanisms. Am J Transplant 2007; 7:1121-1130.
6. Hidalgo LG, Einecke G, Allanach K, et al. The transcriptome of human cytotoxic T cells: measuring the burden of CTL-associated transcripts in human kidney transplants. Am J Transplant 2008; 8:637-646.
7. Allanach K, Mengel M, Einecke G, et al. Comparing microarray versus RT-PCR assessment of renal allograft biopsies: similar performance despite different dynamic ranges. Am J Transplant 2008; 8:1006-1015.
8. Einecke G, Reeve J, Mengel M, et al. Expression of B cell and immunoglobulin transcripts is a feature of inflammation in late allografts. Am J Transplant 2008; 8:1434-1443.
9. Bunnag S, Einecke G, Reeve J, et al. Molecular correlates of renal function in human kidney transplant biopsies. J Am Soc Nephrol 2009; 20:1149-1160.
10. Sis B, Jhangri G, Bunnag S, et al. Endothelial gene expression in kidney transplants with alloantibody indicates antibody-mediated damage despite lack of C4d staining. Am J Transplant 2009; 9:2312-2323.
11. Famulski K, Einecke G, Sis B, Halloran P. High expression of markers of alternative macrophage activation is a feature of canonical T cell mediated rejection. Am J Transplant 2009; 9 (s2):396.
12. Mengel M, Reeve J, Bunnag S, et al. Molecular correlates of scarring in kidney transplants: the emergence of mast cell transcripts. Am J Transplant 2009; 9:169-178.
13. Mengel M, Reeve J, Bunnag S, et al. Scoring total inflammation is superior to the current banff inflammation score in predicting outcome and the degree of molecular disturbance in renal allografts. Am J Transplant 2009; 9:1859-1867.
14. Reeve J, Einecke G, Mengel M, et al. Diagnosing rejection in renal transplants: a comparison of molecular- and histopathology-based approaches. Am J Transplant 2009; 9:1802-1810.
15. Flechner SM, Kurian SM, Head SR, et al. Kidney transplant rejection and tissue injury by gene profiling of biopsies and peripheral blood lymphocytes. Am J Transplant 2004; 4:1475-1489.
16. Sarwal M, Chua MS, Kambham N, et al. Molecular heterogeneity in acute renal allograft rejection identified by DNA microarray profiling. N Engl J Med 2003; 349:125-138. (Pubitemid 36818782)
17. Kissmeyer-Nielsen F, Olsen S, Peterson VP, Fjeldborg O. Hyperacute rejection of kidney allografts associated with preexisting humoral antibodies against donor cells. Lancet 1966; 2:662-665.
18. Halloran PF, Wadgymar A, Ritchie S, et al. The significance of the anti-class I antibody response. I. Clinical and pathologic features of anti-class I-mediated rejection. Transplant 1990; 49:85-91.
19. Halloran PF, Schlaut J, Solez K, Srinivasa NS. The significance of the anticlass I response II. Clinical and pathologic features of renal transplants with anticlass I-like antibody. Transplant 1992; 53:550-555.
20. Trpkov K, Campbell P, Pazderka F, et al. Pathologic features of acute renal allograft rejection associated with donor-specific antibody. Transplant 1996; 61:1586-1592.
21. Feucht HE, Felber E, Gokel MJ, et al. Vascular deposition of complement-split products in kidney allografts with cell-mediated rejection. Clin Exp Immunol 1991; 86:464-470.
22. Feucht HE, Schneeberger H, Hillebrand G, et al. Capillary deposition of C4d complement fragment and early renal graft loss. Kidney Int 1993; 43:1333-1338.
23. Mauiyyedi S, Pelle PD, Saidman S, et al. Chronic humoral rejection: identification of antibody-mediated chronic renal allograft rejection by C4d deposits in peritubular capillaries. J Am Soc Nephrol 2001; 12:574-582.
24. Regele H, BohmigGA, Habicht A, et al. Capillary deposition of complement split product C4d in renal allografts is associated with basement membrane injury in peritubular and glomerular capillaries: a contribution of humoral immunity to chronic allograft rejection. J Am Soc Nephrol 2002; 13:2371-2380.
25. Vongwiwatana A, Gourishankar S, Campbell PM, et al. Peritubular capillary changes and C4d deposits are associated with transplant glomerulopathy but not IgA nephropathy. Am J Transplant 2004; 4:124-129.
26. Sis B, Campbell PM, Mueller T, et al. Transplant glomerulopathy, late antibody- mediated rejection and the ABCD tetrad in kidney allograft biopsies for cause. Am J Transplant 2007; 7:1743-1752.
27. Colvin RB. Antibody-mediated renal allograft rejection: diagnosis and pathogenesis. J Am Soc Nephrol 2007; 18:1046-1056.
28. Reed EF, Demetris AJ, Hammond E, et al. Acute antibody-mediated rejection of cardiac transplants. J Heart Lung Transplant 2006; 25:153-159.
29. McKenna RM, Takemoto SK, Terasaki PI. Anti-HLA antibodies after solid organ transplantation. Transplant 2000; 69:319-326.
30. Mauiyyedi S, Colvin RB. Humoral rejection in kidney transplantation: new concepts in diagnosis and treatment. Curr Opin Nephrol Hypertens 2002; 11:609-618.
31. Miller GG, Destarac L, Zeevi A, et al. Acute humoral rejection of human lung allografts and elevation of C4d in bronchoalveolar lavage fluid. Am J Transplant 2004; 4:1323-1330.
32. Rodriguez ER, Skojec DV, Tan CD, et al. Antibody-mediated rejection in human cardiac allografts: evaluation of immunoglobulins and complement activation products c4d and c3d as markers. Am J Transplant 2005; 5:2778-2785.
33. Drachenberg CB, Odorico J, Demetris AJ, et al. Banff schema for grading pancreas allograft rejection: working proposal by a multidisciplinary international consensus panel. Am J Transplant 2008; 8:1237-1249.
34. Girnita AL, Lee TM, McCurry KR, et al. Antihuman leukocyte antigen antibodies, vascular C4d deposition and increased soluble c4d in bronchoalveolar lavage of lung allografts. Transplant 2008; 86:342-347.
35. Colvin RB, Smith RN. Antibody-mediated organ-allograft rejection. Nat Rev Immunol 2005; 5:807-817.
36. Haas M, Rahman MH, Racusen LC, et al. C4d and C3d staining in biopsies of ABO- and HLA-incompatible renal allografts: correlation with histologic findings. Am J Transplant 2006; 6:1829-1840.
37. Kraus ES, Parekh RS, Oberai P, et al. Subclinical rejection in stable positive crossmatch kidney transplant patients: incidence and correlations. Am J Transplant 2009; 9:1826-1834.
38. Racusen LC, Colvin RB, Solez K, et al. Antibody-mediated rejection criteria: an addition to the Banff 97 classification of renal allograft rejection. Am J Transplant 2003; 3:708-714.
39. Solez K, Colvin RB, Racusen LC, et al. Banff '05 meeting report: differential diagnosis of chronic allograft injury and elimination of chronic allograft nephropathy ('CAN'). Am J Transplant 2007; 7:518-526.
40. Mauiyyedi S, Crespo M, Collins AB, et al. Acute humoral rejection in kidney transplantation: II. Morphology, immunopathology, and pathologic classification. J Am Soc Nephrol 2002; 13:779-787.
41. Feucht HE, Opelz G. The humoral immune response towards HLA class II determinants in renal transplantation[review]. Kidney Int1996;50:1464-1475.
42. Gloor JM, Sethi S, Stegall MD, et al. Transplant glomerulopathy: subclinical incidence and association with alloantibody. Am J Transplant 2007; 7:2124-2132.
43. Terasaki PI, Ozawa M. Predicting kidney graft failure by HLA antibodies: a prospective trial. Am J Transplant 2004; 4:438-443.
44. Einecke G, Sis B, Reeve J, et al. Antibody-mediated microcirculation injury is the major cause of late kidney transplant failure. Am J Transplant 2009; 9:2520-2531.
45. El Zoghby ZM, Stegall MD, Lager DJ, et al. Identifying specific causes of kidney allograft loss. Am J Transplant 2009; 9:527-535.
46. Solez K, Colvin RB, Racusen LC, et al. Banff 07 classification of renal allograft pathology: updates and future directions. Am J Transplant 2008; 8:753-760. (Pubitemid 351347767)
47. Racusen LC, Solez K, Colvin RB, et al. The Banff 97 working classification of renal allograft pathology. Kidney Int 1999; 55:713-723. (Pubitemid 29082898)
48. Jin YP, Jindra PT, Gong KW, et al. Anti-HLA class I antibodies activate endothelial cells and promote chronic rejection. Transplant 2005; 79 (3 Suppl):S19-S21.
49. Regele H, Bohmig GA. Tissue injury and repair in allografts: novel perspectives. Curr Opin Nephrol Hypertens 2003; 12:259-266.
50. Minami K, Murata K, Lee CY, et al. C4d deposition and clearance in cardiac transplants correlates with alloantibody levels and rejection in rats. Am J Transplant 2006; 6 (5 Pt 1):923-932.
51. Valujskikh A, Heeger PS. Emerging roles of endothelial cells in transplant rejection. Curr Opin Immunol 2003; 15:493-498. (Pubitemid 37130187)
52. Baldwin WM III, Kasper EK, Zachary AA, et al. Beyond C4d: other complement- related diagnostic approaches to antibody-mediated rejection. Am J Transplant 2004; 4:311-318.
53. BaldwinWM, LarsenCP, Fairchild RL. Innate immune responses to transplants: a significant variable with cadaver donors. Immunity 2001; 14:369-376.
54. Morrell CN, Murata K, Swaim AM, et al. In vivo platelet-endothelial cell interactions in response to major histocompatibility complex alloantibody. Circ Res 2008; 102:777-785.
55. Hermant B, Bibert S, Concord E, et al. Identification of proteases involved in the proteolysis of vascular endothelium cadherin during neutrophil transmigration. J Biol Chem 2003; 278:14002-14012.
56. Hamik A, Lin Z, Kumar A, et al. Kruppel-like factor 4 regulates endothelial inflammation. J Biol Chem 2007; 282:13769-13779.
57. Cermenati S, Moleri S, Cimbro S, et al. Sox18 and Sox7 play redundant roles in vascular development. Blood 2008; 111:2657-2666.
58. Goes N, Urmson J, Hobart M, Halloran PF. The unique role of interferongamma in the regulation of MHC expression on arterial endothelium. Transplant 1996; 62:1889-1894.
59. Hidalgo LG, Campbell PM, Sis B, et al. De novo donor specific antibody at the time of kidney transplant biopsy associates with microvascular pathology and late graft failure. Am J Transplant 2009; 9:2532-2541.
60. Yamakuchi M, Kirkiles-Smith NC, Ferlito M, et al. Antibody to human leukocyte antigen triggers endothelial exocytosis. Proc Natl Acad Sci U S A 2007; 104:1301-1306.
61. Sans M, Danese S, de La MC, et al. Enhanced recruitment of CX3CR1+ T cells by mucosal endothelial cell-derived fractalkine in inflammatory bowel disease. Gastroenterology 2007; 132:139-153.
62. Lee CY, Lotfi-Emran S, Erdinc M, et al. The involvement of FcR mechanisms in antibody-mediated rejection. Transplant 2007; 84:1324-1334.
63. Loupy A, Suberbielle-Boissel C, Hill GS, et al. Outcome of subclinical antibody- mediated rejection in kidney transplant recipients with preformed donorspecific antibodies. Am J Transplant 2009; 9:2561-2570.
64. Murata K, Baldwin WM III. Mechanisms of complement activation, C4d deposition, and their contribution to the pathogenesis of antibody-mediated rejection. Transplant Rev (Orlando) 2009; 23:139-150.
65. Wehner JR, Morrell CN, Rene Rodriguez E, et al. Immunological challenges of cardiac transplantation: the need for better animal models to answer current clinical questions. J Clin Immunol 2009. [Epub ahead of print]
66. Pober JS, Min W, Bradley JR. Mechanisms of endothelial dysfunction, injury, and death. Annu Rev Pathol 2009; 4:71-95.
67. Saadi S, Holzknecht RA, Patte CP, Platt JL. Endothelial cell activation by poreforming structures: pivotal role for interleukin-1 alpha. Circulation 2000; 101:1867-1873.
68. Saadi S, Takahashi T, Holzknecht RA, Platt JL. Pathways to acute humoral rejection. Am J Pathol 2004; 164:1073-1080.